Pacific Biosciences of California Inc (PACB)
1.375
+0.02
(+1.10%)
USD |
NASDAQ |
Apr 25, 16:00
1.40
+0.02
(+1.82%)
After-Hours: 20:00
Pacific Biosciences of California Enterprise Value: 625.73M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 24, 2024 | 625.73M |
April 23, 2024 | 655.21M |
April 22, 2024 | 679.32M |
April 19, 2024 | 676.64M |
April 18, 2024 | 652.53M |
April 17, 2024 | 636.45M |
April 16, 2024 | 636.45M |
April 15, 2024 | 1.021B |
April 12, 2024 | 1.111B |
April 11, 2024 | 1.167B |
April 10, 2024 | 1.154B |
April 09, 2024 | 1.229B |
April 08, 2024 | 1.186B |
April 05, 2024 | 1.159B |
April 04, 2024 | 1.154B |
April 03, 2024 | 1.162B |
April 02, 2024 | 1.175B |
April 01, 2024 | 1.239B |
March 28, 2024 | 1.266B |
March 27, 2024 | 1.258B |
March 26, 2024 | 1.205B |
March 25, 2024 | 1.229B |
March 22, 2024 | 1.247B |
March 21, 2024 | 1.290B |
March 20, 2024 | 1.285B |
Date | Value |
---|---|
March 19, 2024 | 1.237B |
March 18, 2024 | 1.245B |
March 15, 2024 | 1.277B |
March 14, 2024 | 1.309B |
March 13, 2024 | 1.397B |
March 12, 2024 | 1.336B |
March 11, 2024 | 1.440B |
March 08, 2024 | 1.448B |
March 07, 2024 | 1.491B |
March 06, 2024 | 1.380B |
March 05, 2024 | 1.427B |
March 04, 2024 | 1.569B |
March 01, 2024 | 1.652B |
February 29, 2024 | 1.743B |
February 28, 2024 | 1.754B |
February 27, 2024 | 1.767B |
February 26, 2024 | 1.663B |
February 23, 2024 | 1.631B |
February 22, 2024 | 1.636B |
February 21, 2024 | 1.623B |
February 20, 2024 | 1.679B |
February 16, 2024 | 1.799B |
February 15, 2024 | 2.049B |
February 14, 2024 | 2.003B |
February 13, 2024 | 1.890B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
265.38M
Minimum
Apr 03 2020
9.558B
Maximum
Feb 11 2021
2.481B
Average
2.083B
Median
Enterprise Value Benchmarks
Cerus Corp | 315.67M |
Axogen Inc | 312.41M |
AVITA Medical Inc | 171.06M |
BioSig Technologies Inc | 14.62M |
Intellia Therapeutics Inc | 1.122B |
Enterprise Value Related Metrics
Net Income (Quarterly) | -82.02M |
Revenue (Quarterly) | 58.36M |
Total Expenses (Quarterly) | 144.74M |
EPS Diluted (Quarterly) | -0.31 |
Gross Profit Margin (Quarterly) | 16.40% |
Profit Margin (Quarterly) | -140.5% |
Earnings Yield | -88.00% |
Normalized Earnings Yield | -80.70 |